Deep Dive Into EyePoint Pharmaceuticals Stock: Analyst Perspectives (4 Ratings)


4 analysts have expressed a variety of opinions on EyePoint Pharmaceuticals EYPT over the past quarter, offering a diverse set of opinions from bullish to bearish.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 4 0 0 0 0
Last 30D 2 0 0 0 0
1M Ago 0 0 0 0 0
2M Ago 1 0 0 0 0
3M Ago 1 0 0 0 0

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $32.5, a high estimate of $39.00, and a low estimate of $28.00. A 7.8% drop is evident in the current average compared to the previous average price target of $35.25.

Investigating Analyst Ratings: An Elaborate Study

The analysis of recent analyst actions sheds light on the perception of EyePoint Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Daniil Gataulin Chardan Capital Lowers Buy $28.00 $39.00
Graig Suvannavejh Mizuho Lowers Buy $30.00 $39.00
Yi Chen HC Wainwright & Co. Maintains Buy $33.00 $33.00
Graig Suvannavejh Mizuho Raises Buy $39.00 $30.00

Key Insights:

  • Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to EyePoint Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.
  • Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of EyePoint Pharmaceuticals compared to the broader market.
  • Price Targets: Analysts predict movements in price targets, offering estimates for EyePoint Pharmaceuticals's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into EyePoint Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on EyePoint Pharmaceuticals analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering EyePoint Pharmaceuticals: A Closer Look

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals's Economic Impact: An Analysis

Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

Revenue Growth: EyePoint Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 33.18%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: EyePoint Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -100.51%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): EyePoint Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -8.68%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): EyePoint Pharmaceuticals's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -5.47%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: EyePoint Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.02, reflecting a lower dependency on debt financing and a more conservative financial approach.

The Basics of Analyst Ratings

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!